Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: first ever gene editing FDA nod; US FTC ruffles pharma’s feathers; AstraZeneca pays to play in RSV; Syndax leukemia drug makes splash at ASH; BMS bets big on Chinese ADC.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 15 December 2023, including: first ever gene editing FDA nod; US FTC ruffles pharma’s feathers; AstraZeneca PLC pays to play in RSV; Syndax Pharmaceuticals, Inc. leukemia drug makes splash at ASH; and Bristol Myers Squibb Company bets big on a Chinese ADC.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Vertex/CRISPR Nab First-Ever Gene Editing FDA Nod, Overshadow Bluebird’s Same-Day Win" - Scrip, 9 Dec, 2023.)
(Also see "US FTC Ruffles Pharma’s Feathers Again" - Scrip, 12 Dec, 2023.)
(Also see "AstraZeneca Pays Big To Get Into RSV" - Scrip, 12 Dec, 2023.)
(Also see "Syndax’s Revumenib Makes Splash At ASH As Company Eyes Blockbuster Opportunity" - Scrip, 12 Dec, 2023.)
(Also see "BMS Bets $8.4bn On Biokin’s Bispecific ADC" - Scrip, 12 Dec, 2023.)